Consensus Tempus AI, Inc. Boerse Muenchen

Stocks

F3M

US88023B1035

Biotechnology & Medical Research

Real-time Boerse Muenchen 06:53:40 09/10/26 am AEDT			5-day change	1st Jan Change
61.64 ^EUR	-2.58%		-12.00%	+21.67%

08/10	Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug	DJ
08/10	Tempus Expands Moderna, Merck Collaboration for Individualized Cancer Therapy	MT

3358c8c4430b805f672174.dZSDp4042OTWL_44xClMuqLwE483FdUGLBgS6QRovtg.AuHy0btQs7yaRadboHMI2eaoPrlaY7JEW3RBsV4y270h_8KTtHOJkpVwyg~1f029fc98b1f734737a85291f5b29281

Analysts' recommendations: Tempus AI, Inc.

21/09	Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target	MT
09/09	UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target	MT
08/09	Rothschild & Co Redburn Initiates Tempus AI at Neutral With $67 Price Target	MT
02/09	Cantor Fitzgerald Initiates Tempus AI at Overweight With $80 Price Target	MT
01/09	Piper Sandler Upgrades Tempus AI to Overweight From Neutral, Adjusts PT to $76 From $56	MT
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
21/07	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
21/07	Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers	MT
21/07	Top Midday Decliners	MT
13/04	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
13/04	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
25/02	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
19/02	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
17/02	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
02/12	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11/11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
22/10/25	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
22/10/25	Tempus AI Shares Lower After TD Cowen Downgrade	MT
21/10/25	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
20/10/25	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
02/09/25	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
06/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
21/04/25	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
27/02/25	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
26/02/25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+13.99%
	ARGENX SE					+24.63%
	LONZA GROUP AG					+19.23%
	REVOLUTION MEDICINES, INC.					+28.86%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+19.55%
	CELLTRION, INC.					+45.91%
	BIONTECH SE					+22.24%
	INSMED INCORPORATED					+94.36%
	Average					+31.33%
	Weighted average by Cap.					+26.15%